Literature DB >> 7712474

Expression of Sia alpha 2-->6Gal beta 1-->4GlcNAc residues on sugar chains of glycoproteins including carcinoembryonic antigens in human colon adenocarcinoma: applications of Trichosanthes japonica agglutinin I for early diagnosis.

K Yamashita1, K Fukushima, T Sakiyama, F Murata, M Kuroki, Y Matsuoka.   

Abstract

The N-linked sugar chain structures of the carcinoembryonic antigen (CEA) produced by liver metastases of colon cancers and the normal counterpart of CEA purified from human adult feces (NFA-2) were previously determined comparatively (K. Fukushima, T. Ohkura, M. Kanai, M. Kuroki, Y. Matsuoka, A. Kobata, and K. Yamashita. Glycobiology, 5:105-115, 1995). Seventy-five % of NFA-2 contained complex type sugar chains with Gal beta 1-->3GlcNAc residues, in contrast to the sugar chains of CEA, in which over 90% of the oligosaccharides contained Gal beta 1-->4GlcNAc residues, and Sia alpha 2-->6Gal beta 1-->4GlcNAc residues were detected in 18 to 65% of the oligosaccharides. The expression of Sia alpha 2-->6Gal beta 1-->4GlcNAc residues on CEA molecules in sera and tissues was investigated using Trichosanthes japonica agglutinin I (TJA-I), which interacts with Sia alpha 2-->6Gal beta 1-->4 GlcNAc residues. Ten purified CEA samples bound to a TJA-I column while seven NFA-2 samples passed through the column. Various concentrations of serum CEA samples from patients with metastatic colon cancers exclusively bound to the TJA-I column, reflecting that CEA molecules exfoliated into the blood circulation comprise sugar chains with Sia alpha 2-->6Gal beta 1-->4GlcNAc residues. In histochemical studies involving biotinylated TJA-I, normal mucosa (n = 20) and benign adenomas (n = 20) were not stained, and 83% of well and moderately differentiated colon adenocarcinomas (n = 53) reacted with TJA-I, although poorly differentiated ones (n = 9) and mucinous specimens (n = 10) were negative. Because over 90% of colon adenocarcinomas can be differentiated, TJA-I staining might be applicable to the early diagnosis of colon cancers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7712474

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Sialyltransferases in cancer.

Authors:  F Dall'Olio; M Chiricolo
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

2.  Protein glycosylation in cancer biology: an overview.

Authors:  F Dall'olio
Journal:  Clin Mol Pathol       Date:  1996-06

Review 3.  Perspectives on the significance of altered glycosylation of glycoproteins in cancer.

Authors:  Y J Kim; A Varki
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

Review 4.  The sialyl-alpha2,6-lactosaminyl-structure: biosynthesis and functional role.

Authors:  F Dall'Olio
Journal:  Glycoconj J       Date:  2000-10       Impact factor: 2.916

5.  Structure and binding analysis of Polyporus squamosus lectin in complex with the Neu5Ac{alpha}2-6Gal{beta}1-4GlcNAc human-type influenza receptor.

Authors:  Renuka Kadirvelraj; Oliver C Grant; Irwin J Goldstein; Harry C Winter; Hiroaki Tateno; Elisa Fadda; Robert J Woods
Journal:  Glycobiology       Date:  2011-03-24       Impact factor: 4.313

6.  The metastatic stage-dependent mucosal expression of sialic acid is a potential marker for targeting colon cancer with cationic polymers.

Authors:  Abdel Kareem Azab; Jackie Kleinstern; Morris Srebnik; Abraham Rubinstein
Journal:  Pharm Res       Date:  2007-10-25       Impact factor: 4.200

7.  Recognition of acetylated oligosaccharides by human L-ficolin.

Authors:  Anders Krarup; Daniel A Mitchell; Robert B Sim
Journal:  Immunol Lett       Date:  2008-04-28       Impact factor: 3.685

8.  Alteration of N-glycosylation in the kidney in a mouse model of systemic lupus erythematosus: relative quantification of N-glycans using an isotope-tagging method.

Authors:  Noritaka Hashii; Nana Kawasaki; Satsuki Itoh; Yukari Nakajima; Toru Kawanishi; Teruhide Yamaguchi
Journal:  Immunology       Date:  2008-08-14       Impact factor: 7.397

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.